The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...
In an interview, Dr. David A. Taub highlighted Prostate Cancer Awareness Month by outlining current treatment options for patients with prostate cancer. In an interview with CURE, Dr. David A. Taub ...
As a physician, researcher, and biotech leader with personal experience of prostate cancer in my family, I’ve long advocated for putting patients first in our quest for medical innovation. Today, I ...
Have you or a loved one been diagnosed with prostate cancer? Understanding the various treatment options available for different stages of this disease can empower you to make informed decisions.
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Enolen is currently being studied in a Phase 1 trial evaluating its safety, tolerability and preliminary efficacy for localized sustained delivery of enzalutamide into the prostate. Alessa expects to ...
An estimated 1 in 8 men will be diagnosed with prostate cancer in their lifetime, often after 65. And as terrifying as that number is, a diagnosis isn’t always quite what it seems. Today, the vast ...
Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...
“For localised prostate cancer, treatment options include surgery or radiotherapy. Both give equivalent cure rates,” Dr Komen ...
Former president Joe Biden was diagnosed with an aggressive form of prostate cancer, his spokesperson announced on Sunday. Biden, 82, is currently reviewing his treatment options with his family and ...
In our news wrap Sunday, former President Biden has been diagnosed with an aggressive form of prostate cancer, Pope Leo XIV delivered his inaugural Mass at St. Peter’s Square, Israel’s military said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback